Background: Pomalidomide, a potent novel immunomodulatory agent, has been developed as a racemic mixture of its R-and S-isomers. Pharmacokinetic (PK) analyses were conducted to determine the PK disposition of the isomers from their PK profiles in humans and monkeys.
Introduction
Pomalidomide (CC-4047) (Fig. 1) is a novel immunomodulatory agent with pleiotropic cytotoxic effects against multiple myeloma cells ( Mitsiades et al., 2002; Zhu et al., 2008) , as well as antiproliferative (Hideshima et al., 2000; Verhelle et al., 2007) , anti-angiogenic (Gupta et al., 2001; Reddy et al., 2008; Lu et al., 2009) , and immunomodulatory actions (Corral et al., 1999; Hayashi et al., 2005; Reddy et al., 2008) . It has potent effects on key cytokines including tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and interferon-γ (IFN-γ) (Teo et al., 2003) . Potential therapeutic benefits have been shown in the treatment of various hematologic and nonneoplastic hematologic disorders. Pomalidomide is currently approved in the US (Pomalyst ® ) (Celgene Corporation, 2005 -2013 and Europe (Imnovid ® ) for the treatment of relapsed/refractory multiple myeloma in patients who have received at least two prior therapies including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also undergoing clinical evaluation for the treatment of myelofibrosis and systemic sclerosis.
Pomalidomide is a chiral compound with an asymmetric carbon center and can therefore exist as the optically active forms of S (-) and R (+). The S-isomer is termed CC-5083 and the Risomer is termed CC-6016. The R-and S-isomers exist in a 50:50 ratio and interconvert in plasma via enzymatic and non-enzymatic pathways (Hoffmann et al., 2013) . Pomalidomide has been developed as a racemic mixture of its R-and S-isomers even though the S-isomer of pomalidomide has been reported to be the more potent enantiomer of the racemate (Teo et al., 2003) , and in vitro studies have shown that the anti-TNF-α and immunomodulatory activities are primarily due to the S-isomer (Corral et al., 1996; Muller et al., 1999; Davies et al., 2001) .
variability in PK parameters, the inter-individual variability was modeled as:
(Eq. 1)
where P was the typical value of the parameter in the population, P i was the value of the parameter for the ith individual, and η i was a random inter-individual effect in the parameter for the ith subject with a mean of zero and variance
Intra-individual or residual variability (RV) was modeled as follows:
where C mij was the model-predicted jth concentration in the ith subject, Cij was the observed jth concentration in the ith subject, and ε ij was the random residual effect for the jth concentration in the ith subject with a mean of zero and variance of σ 2 .
PK analysis of the concentration-time data of pomalidomide (CC-4047, CC-5083, and CC-6016) in monkeys and humans was conducted using the nonlinear mixed-effect modeling program (NONMEM) (version 7.2 or higher, Globomax, Ellicott City, MD, US 
Monte Carlo Simulation
A Monte Carlo simulation was performed using NONMEM to probe whether the anticipated exposure of two enantiomers were comparable after dosing of each individual R-or S-isomer in humans. The dose of each individual isomer of 2 mg was simulated at steady state. The PK profiles and exposure for two individuals under each scenario were compared.
Results

Pharmacokinetics in Monkeys
The values (~5%) as compared to the population estimates. The diagnostic plots showed good agreement between population-predicted and individual observed values, and no systematic bias could be identified in the weighted residual plot (data not shown), suggesting that the
Based on the final model derived from human data, Monte Carlo simulations were performed to assess the difference in plasma exposures of the two enantiomers following p.o. dosing of each individual R-or S-isomer in humans. The results are shown in Fig. 8 .
After administration of 2 mg of S-isomer (CC-5083) or R-isomer (CC-6016), comparable PK profiles between R-and S-isomers were observed. Monte Carlo simulation showed that after administration of 2 mg of S-isomer (CC-5083), the drug exposures (AUC inf ) were 105.7 and 92.7 ng/ml*h for S-isomer (CC-5083) and R-isomer (CC-6016), respectively, and after administration of 2 mg of R-isomer (CC-6016), the drug exposures (AUC inf ) were 90.0 and 104.9 ng/ml*h for Sisomer (CC-5083) and R-isomer (CC-6016), respectively, indicating comparable drug exposure between R-and S-isomers after dosing of each individual R-or S-isomer in humans.
Discussion
Pomalidomide exists as a racemic mixture of R-and S-isomer (50:50). The S-isomer of pomalidomide has been reported to be the more potent enantiomer of the racemate (Teo et al., 2003) , and in vitro studies have shown that the anti-TNF-α and immunomodulatory activities are primarily due to the S-isomer (Corral et al., 1996; Muller et al., 1999; Davies et al., 2001) . In the present study, we analyzed in vivo PK data and identified interesting disposition differences between the two enantiomers CC-5083 and CC-6016 in monkeys and humans. A PK model was developed to describe the difference in kinetics of S-and R-isomer (CC-5083 and CC-6016) disposition in monkeys and humans, and it derived a dimensionless factor of the relative ratio of the elimination rate constant versus the interconversion rate constant that drives the PK exposure difference between the two enantiomers in vivo. For pomalidomide, in monkeys, the in vivo elimination rate constants of R-and S-isomers are comparable or higher than the interconversion rate constant (Table 2) , resulting in differences in isomer exposure after dosing individual isomers or racemate (Figs. 3 and 4) . However, in humans, the in vivo elimination rate constants are lower than the interconversion rate constant between R-and S-isomers, which allows the racemization between R-and S-isomers in a clinically meaningful time frame, resulting in small difference in isomer exposures after dosing the racemate (Fig. 5) . In addition, the Monte Carlo simulation of human data in this study showed the comparable PK profiles and comparable drug exposures between R-and S-isomers after administration of a single dose of either S-or R-isomer provided the scientific basis for the development of racemate pomalidomide (Fig. 8) . Therefore, the development of a single pomalidomide enantiomer will not confer a clinical/therapeutic advantage over the racemate.
A chiral center confers different spatial orientation of the enantiomers, and thus often results in differing pharmacologic effects. It has been long accepted that most of the biological activity observed for a racemate often likely resides within a single enantiomer. It was estimated that before the 1990s, nearly 50% of all drugs used were racemate (Walther and Netscher, 1996) .
However, regulatory agencies' interest in evaluating each enantiomer in a racemate spurred development of single enantiomers, which now account for 55% of the new molecular entities approved by the US Food and Drug Administration (FDA) (Agranat et al., 2012) .
Although the decision to develop a single enantiomer product should include both scientific and economic rationales (Blake and Raissy, 2013) , poor understanding of the kinetics of each individual enantiomer, especially the interplay between enantiomer racemization and difference in enantiomer elimination, can still lead to redundant investment in developing an enantiomer over the racemate. Levalbuterol, the R-enantiomer of albuterol, was introduced in the US market in 1999 based on the fact that the R-enantiomer is stereo-selective at the target receptor with a 68-fold greater potency than the S-enantiomer (Brittain et al., 1973) . However, a randomized crossover study in which the racemate and the R-and S-enantiomers were administered demonstrated that the therapeutic ratio of the R-enantiomer was comparable with that of the racemate in asthma patients (Lotvall et al., 2001) , which might be due to the limited The R-enantiomer of thalidomide is effective against morning sickness, while the S-enantiomer is teratogenic, causing birth defects (Trapnell, 1998) . However, there is no rationale for developing a single enantiomer drug of thalidomide, since the single enantiomer is converted into a racemate within a clinically meaningful time frame in vivo (Eriksson et al., 2001 ). All these cases indicate that kinetic properties including racemization and elimination of enantiomers play a critical role in the decision whether to develop an enantiomer or a racemate in addition to using only data on in vitro stereo-selectivity at the target receptor. However, the development of single enantiomer drugs from established or previously marketed racemates may still have the potential benefits of less complex, more selective pharmacodynamic profiles, potential for an improved therapeutical index, less toxicity, and reduced potential for complex drug interactions (Hutt and Valentova, 2003; Mansfield et al., 2004) . This was successfully demonstrated by the non-steroidal anti-inflammatory drugs dexketoprofen and dexibuprofen, the proton pump inhibitor esomeprazole, the antimicrobial levofloxacin, the selective serotonin reuptake inhibitor escitalopram, the anesthetic ketamine, the histamine H1-receptor antagonist levocetirizine, etc.
( Hutt and Valentova, 2003) . The decision of whether to develop the racemate or its enantiomers requires scientific justification based on quality, safety, and efficacy, together with the riskbenefit ratio.
The scientific decision tree to inform the development of an active enantiomer from a racemate begins with confirmation of stereo-selectivity in receptor recognition and includes in vivo efficacy (Blake and Raissy, 2013) . Importantly, the active enantiomer must not racemize (interconvert In order to explore the sensitivity of the drug exposure of the R-and S-isomers in relation to the elimination rate constant and the interconversion rate constant, a dimensionless factor for the relative ratio of elimination/interconversion rate was proposed. The PK exposure ratios between the R-and S-isomers were simulated following different scenarios of dimensionless factors.
The simulation showed that the higher the ratio of the elimination rate constant over the interconversion rate constant, the larger the differences in PK exposures between the R-and Sisomers. Therefore, the potential difference to isomer exposure is primarily determined by the ratio of the rate of elimination over the rate of the interconversion, and secondarily to potential differences in isomer PK disposition. This quantitative measure can aid in determining if a new single enantiomer product might or might not confer any clinical advantages over the racemate.
In conclusion, a population PK model was successfully developed to describe the PK disposition of R-and S-isomers in monkeys and in humans in vivo. The model was able to predict the comparable PK profiles and comparable drug exposures of R-and S-isomers after dosing of a single isomer. The relatively slower elimination rate constant as compared to the interconversion rate constant in humans may result in fast racemization between R-and Sisomers, indicating no clinical/therapeutic advantage of developing single-enantiomer pomalidomide versus developing racemate pomalidomide. 
